Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA/CD19 Dual Targeted CAR-T Cell in Autoimmune Kidney Diseases
NCT06285279Phase 1Recruiting
- Sponsor
- Nanjing University School of Medicine
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FKC289 in lupus nephritis (LN), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), membranous nephropathy (MN) and 1 more, sponsored by Nanjing University School of Medicine. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 24 weeks. Started Mar 2024; status: recruiting.
02
Drugs
FKC289
03
Conditions
lupus nephritis (LN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)membranous nephropathy (MN)IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT06285279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285279.